TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11743700

Group type: EXPERIMENTAL
Intervention: Thermal sensory testing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Abnormal neurological examination
Number of subjects: 24
Study: 9487840

Group type: EXPERIMENTAL
Intervention: Sonicare sonic toothbrush
Number of subjects: 24

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 24
Study: 8437319

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (EPN)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (usual conservative therapy)
Number of subjects: 86
Study: 3518048

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus tobramycin (150 mg/kg body weight/24 h ceftazidime + 10 mg/kg body weight/24 h tobramycin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ceftazidime alone (150 mg/kg body weight/24 h)
Number of subjects: 20
Study: 30898322

Group type: EXPERIMENTAL
Intervention: Prophylactic EGCG (arm A)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Therapeutic EGCG (arm B)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional therapy (arm C)
Number of subjects: 83
Study: 30578206

Group type: EXPERIMENTAL
Intervention: E0302 50 mg intramuscular injection twice a week for 16 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 26228097

Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action (DA)
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1107
Study: 24120303

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (risperidone or aripiprazole)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 14
Study: 22969201

Group type: EXPERIMENTAL
Intervention: Faringel (10 mL)
Number of subjects: 40
Study: 19958532

Group type: EXPERIMENTAL
Intervention: CVVH at 4 L/h for 60 min then 2 L/h
Number of subjects: 14

Group type: COMPARATOR
Intervention: CVVH at 2 L/h for 60 min then 4 L/h
Number of subjects: 14
Study: 17332197

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (60 to 90 seconds) with maternal administration of syntocinon
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional delivery (control group)
Number of subjects: 39
Study: 15555219

Group type: COMPARATOR
Intervention: etoposide/cisplatin
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: epirubicin/cisplatin
Number of subjects: 402
Study: 11464426

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 453

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 453
Study: 7994616

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol (CPT) and sub-therapeutic doses of cyclosporine A (CsA) at 2mg/kg/d
Number of subjects: 0
Study: 3051519

Group type: EXPERIMENTAL
Intervention: Respirable sulfuric acid aerosol at concentrations of 0, 380, 1060, and 1520 micrograms/m3
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Respirable sulfuric acid aerosol at concentrations of 1060 and 1520 micrograms/m3
Number of subjects: 42
Study: 31952497

Group type: EXPERIMENTAL
Intervention: Parent-adolescent communication regarding sexual and reproductive health
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Discussions with friends/peers
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Qualitative insights from parents
Number of subjects: 1057
Study: 30377862

Group type: EXPERIMENTAL
Intervention: CRP/PALB < 17.7 (LCP) group
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: CRP/PALB ≥ 17.7 (HCP) group
Number of subjects: 401

Group type: COMPARATOR
Intervention: CRP/PALB
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: HCP group
Number of subjects: 401
Study: 28576734

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cancer Recovery (MBCR)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Tai Chi/Qigong (TCQ)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Immediate intervention (either MBCR or TCQ)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Exploratory analyses
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Health economic measures
Number of subjects: 600
Study: 25365723

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33 °C (TTM33)
Number of subjects: 920

Group type: COMPARATOR
Intervention: Targeted temperature management at 36 °C (TTM36)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: High vasopressor group
Number of subjects: 920

Group type: COMPARATOR
Intervention: Low vasopressor group
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure
Number of subjects: 920
Study: 23446684

Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg/day
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Pridopidine 90 mg/day
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Pridopidine (combined 45 mg/day and 90 mg/day)
Number of subjects: 386
Study: 21402327

Group type: EXPERIMENTAL
Intervention: Mental practice (experimental group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Relaxation (control group)
Number of subjects: 47
Study: 19729520

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 17014274

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Number of subjects: 217

Group type: COMPARATOR
Intervention: No feedback (Control)
Number of subjects: 217
Study: 12809962

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg IV
Number of subjects: 75

Group type: COMPARATOR
Intervention: Droperidol 20 microg/kg IV
Number of subjects: 75

Group type: COMPARATOR
Intervention: Metoclopramide 0.2 mg/kg IV
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 75
Study: 11072441

Group type: EXPERIMENTAL
Intervention: 2-mg nicotine gum
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: 4-mg nicotine gum
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study: 9212119

Group type: EXPERIMENTAL
Intervention: Oral ketorolac 10 mg every 6 h for up to 3 days
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Hydrocodone 7.5 mg plus acetaminophen 750 mg every 6 h for up to 3 days
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo capsules followed by ketorolac 10 mg every 6 h for up to 3 days
Number of subjects: 252
Study: 8190292

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) of the left motor cortex
Number of subjects: 10

Group type: COMPARATOR
Intervention: No TMS (control condition)
Number of subjects: 10
Study: 3067374

Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 52
Study: 31491535

Group type: EXPERIMENTAL
Intervention: Retrieval of online Problem‐Solving Therapy (PST) sessions
Number of subjects: 95

Group type: COMPARATOR
Intervention: Rehearsal of online Problem‐Solving Therapy (PST) sessions
Number of subjects: 95
Study: 29914814

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAC)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Both CAC and RFA
Number of subjects: 222
Study: 26949691

Group type: EXPERIMENTAL
Intervention: SB predilation before stenting the main branch (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No predilation (Control group, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SB predilation
Number of subjects: 60
Study: 26116425

Group type: EXPERIMENTAL
Intervention: Erdosteine 900 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Erdosteine 600 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23860343

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg infusion
Number of subjects: 9
Study: 21663622

Group type: COMPARATOR
Intervention: Standard macronutrient content (maximum protein 2.8 g/kg/day; lipid 2.8 g/kg/day, dextrose 10%)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Higher macronutrient content (maximum protein 3.8 g/kg/day; lipid 3.8 g/kg/day, dextrose 12%)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard macronutrient content
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Higher macronutrient content
Number of subjects: 150
Study: 18499010

Group type: EXPERIMENTAL
Intervention: Bimanual phacoemulsification
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard coaxial phacoemulsification
Number of subjects: 180

Group type: COMPARATOR
Intervention: Microcoaxial phacoemulsification
Number of subjects: 180
Study: 16598443

Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg orally before PCI, uptitrated to 50 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metoprolol (50 mg orally before PCI, uptitrated to 150 mg daily)
Number of subjects: 100
Study: 14604447

Group type: EXPERIMENTAL
Intervention: Fluvoxamine CR (100-300 mg/d)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 10893476

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 45
Study: 9430864

Group type: EXPERIMENTAL
Intervention: HighBic. (40 mmol/l) bicarbonate dialysate
Number of subjects: 46

Group type: COMPARATOR
Intervention: LowBic. (30 mmol/l) bicarbonate dialysate
Number of subjects: 46
Study: 8505940

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 3799495

Group type: EXPERIMENTAL
Intervention: Pumpkin-seed supplementation 60 mg X kg body wt-1 X day-1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Orthophosphate supplementation 60 mg X kg body wt-1 X day-1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxalate supplementation 5 mg X kg-1 body wt X day-1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (before treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Posttreatment
Number of subjects: 20
Study: 29107430

Group type: EXPERIMENTAL
Intervention: MAPS (eAlert! System)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control (telephone follow-up only)
Number of subjects: 197
Study: 27483038

Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D supplementation (1,000 mg of elemental calcium as calcium carbonate with 400 IU of vitamin D3 daily)
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282

Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D supplementation
Number of subjects: 36282
Study: 23644937

Group type: EXPERIMENTAL
Intervention: Transoral laser microsurgery (TLM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lip-split mandibulotomy (LSM)
Number of subjects: 24
Study: 22990161

Group type: EXPERIMENTAL
Intervention: Microcurrent (n=8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (n=6)
Number of subjects: 14
Study: 20525445

Group type: EXPERIMENTAL
Intervention: Sonoelastography
Number of subjects: 30

Group type: COMPARATOR
Intervention: B-mode ultrasound
Number of subjects: 30
Study: 18165640

Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index score (CCIS) 1
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: CCIS equal to or greater than 1
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Age greater than 65 years
Number of subjects: 1255
Study: 15711271

Group type: EXPERIMENTAL
Intervention: Ketoconazole (KT) plus hydrocortisone (H) plus alendronate (AL) (1,200 mg daily KT, 30 mg daily H, 40 mg daily AL)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ketoconazole (KT) plus hydrocortisone (H) (1,200 mg daily KT, 30 mg daily H)
Number of subjects: 72
Study: 12825799

Group type: EXPERIMENTAL
Intervention: Thrombolysis, no transport (Group A)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Thrombolysis during transport to an angioplasty centre (Group B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Transport for primary angioplasty (Group C)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (Thrombolysis at nearest hospital)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 300

Group type: COMPARATOR
Intervention: Thrombolysis during transport vs. transport for primary angioplasty alone
Number of subjects: 300
Study: 11860783

Group type: EXPERIMENTAL
Intervention: Essential hypertensive patients
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 297
Study: 8843295

Group type: EXPERIMENTAL
Intervention: Rifampin (300 mg daily for 14 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rifabutin (300 mg daily for 14 days)
Number of subjects: 12
Study: 1364608

Group type: EXPERIMENTAL
Intervention: Silicic enterosorbent 'Polysorba'
Number of subjects: 107
Study: 3881051

Group type: EXPERIMENTAL
Intervention: 0.0 mg of oral physostigmine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5 mg of oral physostigmine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.0 mg of oral physostigmine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.5 mg of oral physostigmine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2.0 mg of oral physostigmine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dose associated with least severe symptoms
Number of subjects: 12
Study: 29907435

Group type: EXPERIMENTAL
Intervention: Deep Subfascial approach
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subfascial approach
Number of subjects: 24
Study: 26086180

Group type: EXPERIMENTAL
Intervention: Short sleep duration (<6 hours/night)
Number of subjects: 7444

Group type: EXPERIMENTAL
Intervention: Long sleep duration (>8 hours/night)
Number of subjects: 7444

Group type: COMPARATOR
Intervention: Normal sleep duration (7 hours/night)
Number of subjects: 7444
Study: 24660159

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (15 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 70
Study: 23522247

Group type: EXPERIMENTAL
Intervention: lamivudine treatment (n=164)
Number of subjects: 256

Group type: COMPARATOR
Intervention: control group (n=92)
Number of subjects: 256
Study: 20530649

Group type: EXPERIMENTAL
Intervention: Eccentric endurance training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Concentric training
Number of subjects: 14
Study: 18671947

Group type: EXPERIMENTAL
Intervention: A. senticosus supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (calcium)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Treatment group (calcium plus A. senticosus)
Number of subjects: 40
Study: 15986343

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice a day for 30 months
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 431
Study: 12566640

Group type: EXPERIMENTAL
Intervention: 10% sucrose rinse, 5 times daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10% sucrose rinse, 10 times daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no mouth rinses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5% sucrose rinse, 5 times daily
Number of subjects: 16
Study: 10336571

Group type: EXPERIMENTAL
Intervention: 12 mg tablet (fasted)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 12 mg tablet (fed)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 mg intravenous (i.v.) infusion over 40 min (fasted)
Number of subjects: 12
Study: 7573709

Group type: EXPERIMENTAL
Intervention: Polyspecific snake antivenom
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 63
Study: 2016622

Group type: EXPERIMENTAL
Intervention: Radiotherapy (XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide (VAC) +/- doxorubicin
Number of subjects: 56

Group type: COMPARATOR
Intervention: VAC +/- XRT (IRS-I)
Number of subjects: 56

Group type: COMPARATOR
Intervention: VAC +/- XRT (IRS-II)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Other sites (comparison group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patients with embryonal rhabdomyosarcoma (RMS)
Number of subjects: 56
Study: 6456557

Group type: EXPERIMENTAL
Intervention: Mobilization and manipulation
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo physiotherapy
Number of subjects: 188
Study: 31387822

Group type: EXPERIMENTAL
Intervention: Telephone follow-up (TFU) and 24/7 hotline
Number of subjects: 288

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 288
Study: 31510998

Group type: EXPERIMENTAL
Intervention: 1% permethrin
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 0.2% parasidose (d-phenothrin)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 4% dimeticone
Number of subjects: 77
Study: 27585055

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 52
Study: 26216386

Group type: EXPERIMENTAL
Intervention: SP3 (S‐1 80 mg/m2/day on days 1‐14 and cisplatin 60 mg/m2 on day 1)
Number of subjects: 625

Group type: COMPARATOR
Intervention: SP5 (S‐1 80‐120 mg/day on days 1‐21 and cisplatin 60 mg/m2 on day 1 or 8)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: SP3
Number of subjects: 625

Group type: COMPARATOR
Intervention: SP5
Number of subjects: 625
Study: 24328357

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 12
Study: 22327347

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB‐12 (BB‐12)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Xylitol (X group)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sorbitol (S group)
Number of subjects: 106
Study: 19405802

Group type: EXPERIMENTAL
Intervention: Group A: Local infiltration of port sites with 10 mL of ropivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group B: Infiltration of port sites with 10 mL of ropivacaine and intraperitoneal instillation of 10 mL of ropivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group C: No analgesic treatment
Number of subjects: 30
Study: 17290056

Group type: EXPERIMENTAL
Intervention: Dexrazoxane (DRZ)
Number of subjects: 478

Group type: COMPARATOR
Intervention: No Dexrazoxane (non-DRZ)
Number of subjects: 478
Study: 15457308

Group type: EXPERIMENTAL
Intervention: Self-management (SM) of warfarin using a point-of-care device (Pro Time Microcogulation System)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Physician-management (PM) of warfarin
Number of subjects: 140
Study: 11206237

Group type: EXPERIMENTAL
Intervention: Fexofenadine, 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fexofenadine and montelukast administered concurrently
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 12
Study: 9542492

Group type: EXPERIMENTAL
Intervention: Ibopamine plus prazosin (200 mg single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo plus prazosin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Open evaluation of ibopamine plus prazosin
Number of subjects: 12
Study: 8184117

Group type: EXPERIMENTAL
Intervention: CT-based limited volume irradiation with face masks for field alignment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated CT examinations after simulation
Number of subjects: 0
Study: 2475690

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Conventional formulation of verapamil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 24
Study: 336110

Group type: EXPERIMENTAL
Intervention: d.1 5 hydroxy-tryptophan (600 mg a day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30803543

Group type: EXPERIMENTAL
Intervention: XP-endo Shaper (XP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reciproc Blue (RB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ProTaper Universal (PTU)
Number of subjects: 30
Study: 28327896

Group type: EXPERIMENTAL
Intervention: Infusional bleomycin (90,000 units infusion over 72 hours)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Conventional BEP with weekly bleomycin (30,000 units/week i.v. bolus)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Infusional bleomycin
Number of subjects: 212

Group type: COMPARATOR
Intervention: Conventional BEP with weekly bleomycin
Number of subjects: 212
Study: 25296647

Group type: EXPERIMENTAL
Intervention: Routine care and a sacral prophylactic dressing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study: 23236022

Group type: EXPERIMENTAL
Intervention: 500 μg/d cyanocobalamin for 8 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 μg/d cyanocobalamin for 8 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10 μg/d cyanocobalamin for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20957423

Group type: EXPERIMENTAL
Intervention: Enhanced arm (nurse-delivered adherence intervention with electronic reminder device and counseling)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control arm (standard intervention with educational session, pillbox, and referral to peer support group)
Number of subjects: 70
Study: 19345767

Group type: EXPERIMENTAL
Intervention: Behavioral medicine intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 67
Study: 17718366

Group type: EXPERIMENTAL
Intervention: Moving finger with a raised line present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moving finger with no raised line present
Number of subjects: 0